High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.

Published

Journal Article

BACKGROUND: New agents with activity in mesothelioma are sorely needed. The Cancer and Leukemia Group B (CALGB) therefore performed a phase II study of high-dose paclitaxel in patients with malignant mesothelioma who had no prior chemotherapy. PATIENTS AND METHODS: Thirty-five patients accrued to this multi-institutional phase II study of paclitaxel given as a 24-hour infusion at 250 mg/m2 every three weeks plus filgrastim (G-CSF) 300 mcg subcutaneously days 3-18. RESULTS: There were three (9%) regressions of evaluable disease. The median survival was five months (95% confidence interval (95% CI): 1.9-9.6 months), the one-year survival rate was 14% and the two-year survival rate was 6%. Toxicity was tolerable with one death from pneumonia (without neutropenia) on day 18 and a 23% rate of grade 4 granulocytopenia. CONCLUSIONS: The level of activity seen with paclitaxel is similar to that seen in other CALGB trials of the single agents carboplatin, trimetrexate and 5-azacytidine. Future studies of of paclitaxel (at lower doses) in combination with synergistic agents could be considered.

Full Text

Duke Authors

Cited Authors

  • Vogelzang, NJ; Herndon, JE; Miller, A; Strauss, G; Clamon, G; Stewart, FM; Aisner, J; Lyss, A; Cooper, MR; Suzuki, Y; Green, MR

Published Date

  • May 1999

Published In

Volume / Issue

  • 10 / 5

Start / End Page

  • 597 - 600

PubMed ID

  • 10416012

Pubmed Central ID

  • 10416012

International Standard Serial Number (ISSN)

  • 0923-7534

Digital Object Identifier (DOI)

  • 10.1023/a:1026438215309

Language

  • eng

Conference Location

  • England